The estimated Net Worth of Rashmi Kumar is at least $2.24 Million dollars as of 19 August 2024. Ms. Kumar owns over 7,500 units of Myriad Genetics stock worth over $2,033,862 and over the last 4 years she sold MYGN stock worth over $210,075. In addition, she makes $0 as Independent Director at Myriad Genetics.
Rashmi has made over 1 trades of the Myriad Genetics stock since 2024, according to the Form 4 filled with the SEC. Most recently she sold 7,500 units of MYGN stock worth $210,075 on 19 August 2024.
The largest trade she's ever made was selling 7,500 units of Myriad Genetics stock on 19 August 2024 worth over $210,075. On average, Rashmi trades about 1,250 units every 0 days since 2020. As of 19 August 2024 she still owns at least 77,392 units of Myriad Genetics stock.
You can see the complete history of Ms. Kumar stock trades at the bottom of the page.
Rashmi Kumar serves as Independent Director of the Company. Ms. Kumar is Senior Vice President and Global Chief Information Officer of Hewlett Packard Enterprise Company. She previously served as Senior Vice President, Chief Information Officer, US Pharmaceutical and Global Chief Data Officer at McKesson Corporation. Ms. Kumar received a B.S. from Bihar Institute of Technology and an M.B.A. from University of California, Irvine.
Rashmi's mailing address filed with the SEC is 320, Wakara Way, U of U Research Park, Salt Lake City, Salt Lake County, Utah, 84108, United States.
Over the last 22 years, insiders at Myriad Genetics have traded over $51,783,466 worth of Myriad Genetics stock and bought 61,160 units worth $1,252,955 . The most active insiders traders include Jerry S Lanchbury, Peter D Meldrum, and Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of $563,312. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth $270,500.
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
Myriad Genetics executives and other stock owners filed with the SEC include: